G.Barekat Pharm (XTEH:BRKT1) Debt-to-Equity : 2.11 (As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Debt-to-Equity?

G.Barekat Pharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was IRR10,315,378 Mil. G.Barekat Pharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was IRR255,897 Mil. G.Barekat Pharm's Total Stockholders Equity for the quarter that ended in Mar. 2017 was IRR5,003,506 Mil. G.Barekat Pharm's debt to equity for the quarter that ended in Mar. 2017 was 2.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for G.Barekat Pharm's Debt-to-Equity or its related term are showing as below:

XTEH:BRKT1's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

G.Barekat Pharm Debt-to-Equity Historical Data

The historical data trend for G.Barekat Pharm's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Debt-to-Equity Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

Debt-to-Equity

N/A

2.11

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
Debt-to-Equity	N/A	2.11

Competitive Comparison of G.Barekat Pharm's Debt-to-Equity

For the Biotechnology subindustry, G.Barekat Pharm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G.Barekat Pharm's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where G.Barekat Pharm's Debt-to-Equity falls into.

G.Barekat Pharm Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

G.Barekat Pharm's Debt to Equity Ratio for the fiscal year that ended in Mar. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10315378	+	255897)	/	5003506
	=	2.11

G.Barekat Pharm's Debt to Equity Ratio for the quarter that ended in Mar. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10315378	+	255897)	/	5003506
	=	2.11

G.Barekat Pharm (XTEH:BRKT1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

G.Barekat Pharm Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines